kalvista pharmaceuticals - KALV
KALV
Close Chg Chg %
19.27 0.18 0.93%
Open Market
19.45
+0.18 (0.93%)
Volume: 26.28K
Last Updated:
Apr 9, 2026, 10:03 AM EDT
Company Overview: kalvista pharmaceuticals - KALV
KALV Key Data
| Open $19.25 | Day Range 19.24 - 19.53 |
| 52 Week Range 9.24 - 21.31 | Market Cap $1.03B |
| Shares Outstanding 51.22M | Public Float 37.70M |
| Beta -0.40 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$3.20 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.29M |
KALV Performance
| 1 Week | -3.17% | ||
| 1 Month | 13.75% | ||
| 3 Months | 14.70% | ||
| 1 Year | 67.71% | ||
| 5 Years | -26.31% |
KALV Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
9
Full Ratings ➔
About kalvista pharmaceuticals - KALV
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.
KALV At a Glance
KalVista Pharmaceuticals, Inc.
200 Crossing Boulevard
Framingham, Massachusetts 01702
| Phone | 1-857-999-0075 | Revenue | 73.62M | |
| Industry | Pharmaceuticals: Major | Net Income | -164,286,000.00 | |
| Sector | Health Technology | Employees | 275 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
KALV Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 11.167 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4.731 |
| Enterprise Value to Sales | 10.949 |
| Total Debt to Enterprise Value | 0.353 |
KALV Efficiency
| Revenue/Employee | 267,698.182 |
| Income Per Employee | -597,403.636 |
| Receivables Turnover | 6.514 |
| Total Asset Turnover | 0.251 |
KALV Liquidity
| Current Ratio | 5.582 |
| Quick Ratio | 5.522 |
| Cash Ratio | 5.234 |
KALV Profitability
| Gross Margin | 91.748 |
| Operating Margin | -233.422 |
| Pretax Margin | -232.852 |
| Net Margin | -223.163 |
| Return on Assets | -56.056 |
| Return on Equity | -354.523 |
| Return on Total Capital | -58.362 |
| Return on Invested Capital | -69.626 |
KALV Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 100.963 |
| Total Debt to Total Assets | 84.743 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 95.567 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Kalvista Pharmaceuticals - KALV
Collapse All in section
| All values USD millions. | 2023 | 2024 | 2025 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | - | 73.62M | - |
Sales Growth
| - | - | - | - | - |
Cost of Goods Sold (COGS) incl D&A
| 802.00K | 816.00K | 941.00K | 6.08M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 802.00K | 816.00K | 941.00K | 1.45M | |
Depreciation
| 802.00K | 816.00K | 941.00K | 1.45M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +7.94% | +1.75% | +15.32% | +545.59% | |
Gross Income
| (802.00K) | (816.00K) | (941.00K) | 67.54M | |
Gross Income Growth
| -7.94% | -1.75% | -15.32% | +7,277.68% | |
Gross Profit Margin
| - | - | - | +91.75% | - |
| 2023 | 2024 | 2025 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 110.07M | 148.08M | 192.07M | 239.38M | |
Research & Development
| 80.28M | 94.62M | 76.72M | 55.64M | |
Other SG&A
| 29.79M | 53.46M | 115.34M | 183.74M | |
SGA Growth
| +14.81% | +34.53% | +29.70% | +24.63% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | 1.76M | (3.29M) | - |
EBIT after Unusual Expense
| (110.87M) | (148.90M) | (194.77M) | (168.55M) | |
Non Operating Income/Expense
| 17.96M | 13.80M | 15.49M | 16.48M | |
Non-Operating Interest Income
| 2.23M | 3.90M | 6.43M | 8.68M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | 5.79M | 19.34M | - |
Interest Expense Growth
| - | - | - | +234.36% | - |
Gross Interest Expense
| - | - | 5.79M | 19.34M | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (92.91M) | (135.10M) | (185.07M) | (171.42M) | |
Pretax Income Growth
| -12.83% | -45.41% | -36.99% | +7.37% | |
Pretax Margin
| - | - | - | -232.85% | - |
Income Tax
| - | (8.45M) | (1.62M) | (7.13M) | |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | 8.45M | 5.01M | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (92.91M) | (126.64M) | (183.44M) | (164.29M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (92.91M) | (126.64M) | (183.44M) | (164.29M) | |
Net Income Growth
| -12.83% | -36.31% | -44.85% | +10.44% | |
Net Margin Growth
| - | - | - | -223.16% | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (92.91M) | (126.64M) | (183.44M) | (164.29M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (92.91M) | (126.64M) | (183.44M) | (164.29M) | |
EPS (Basic)
| -3.3311 | -3.4427 | -3.6945 | -3.2276 | |
EPS (Basic) Growth
| +0.99% | -3.35% | -7.31% | +12.64% | |
Basic Shares Outstanding
| 27.89M | 36.79M | 49.65M | 50.90M | |
EPS (Diluted)
| -3.3311 | -3.4427 | -3.6945 | -3.2276 | |
EPS (Diluted) Growth
| +0.99% | -3.35% | -7.31% | +12.64% | |
Diluted Shares Outstanding
| 27.89M | 36.79M | 49.65M | 50.90M | |
EBITDA
| (110.07M) | (148.08M) | (192.07M) | (170.38M) | |
EBITDA Growth
| -14.81% | -34.53% | -29.70% | +11.29% | |
EBITDA Margin
| - | - | - | -231.45% | - |
Snapshot
| Average Recommendation | BUY | Average Target Price | 34.00 | |
| Number of Ratings | 9 | Current Quarters Estimate | -0.271 | |
| FY Report Date | 06 / 2026 | Current Year's Estimate | -0.948 | |
| Last Quarter’s Earnings | -0.465 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -2.03 | Next Fiscal Year Estimate | 0.476 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 8 | 8 | 9 | 7 |
| Mean Estimate | -0.27 | -0.24 | -0.95 | 0.48 |
| High Estimates | -0.02 | 0.25 | 0.59 | 1.06 |
| Low Estimate | -0.43 | -0.92 | -1.66 | -0.39 |
| Coefficient of Variance | -59.43 | -138.97 | -78.85 | 112.94 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 9 | 9 | 9 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Kalvista Pharmaceuticals - KALV
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Kalvista Pharmaceuticals - KALV
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Feb 20, 2026 | Benjamin L. Palleiko CHIEF EXECUTIVE OFFICER; Director | 429,667 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $15 per share | 6,445,005.00 |
| Feb 20, 2026 | Christopher M. Yea CHIEF DEVELOPMENT OFFICER | 1,774 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Christopher M. Yea CHIEF DEVELOPMENT OFFICER | 224,173 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $15 per share | 3,362,595.00 |
| Feb 20, 2026 | Christopher M. Yea CHIEF DEVELOPMENT OFFICER | 225,282 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Paul K. Audhya CHIEF MEDICAL OFFICER | 2,419 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Paul K. Audhya CHIEF MEDICAL OFFICER | 133,087 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $15 per share | 1,996,305.00 |
| Feb 20, 2026 | Paul K. Audhya CHIEF MEDICAL OFFICER | 134,250 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Benjamin L. Palleiko CHIEF EXECUTIVE OFFICER; Director | 2,419 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Benjamin L. Palleiko CHIEF EXECUTIVE OFFICER; Director | 430,705 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Dec 5, 2025 | Nicole Sweeny Chief Commercial Officer | 38,541 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Dec 5, 2025 | Nicole Sweeny Chief Commercial Officer | 43,541 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Dec 5, 2025 | Nicole Sweeny Chief Commercial Officer | 39,728 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $13.45 per share | 534,341.60 |
| Dec 5, 2025 | Nicole Sweeny Chief Commercial Officer | 81,250 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Dec 5, 2025 | Nicole Sweeny Chief Commercial Officer | 50,000 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 21, 2025 | Paul K. Audhya CHIEF MEDICAL OFFICER | 8,056 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 21, 2025 | Benjamin L. Palleiko CHIEF EXECUTIVE OFFICER; Director | 13,889 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 21, 2025 | Christopher M. Yea CHIEF DEVELOPMENT OFFICER | 4,861 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |